Qiagen (NYSE:QGEN) Sets New 52-Week Low – Time to Sell?

Qiagen N.V. (NYSE:QGEN) shares reached a new 52-week low on Friday . The stock traded as low as $38.89 and last traded at $38.9710, with a volume of 195374 shares traded. The stock had previously closed at $39.71.

Wall Street Analysts Forecast Growth

QGEN has been the topic of several research reports. Barclays set a $58.00 price objective on shares of Qiagen and gave the stock an “overweight” rating in a research note on Friday, February 6th. UBS Group set a $52.00 price objective on Qiagen in a research report on Monday, February 9th. Robert W. Baird set a $53.00 price target on Qiagen in a research report on Friday, February 6th. Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Citigroup reduced their price objective on shares of Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Qiagen has an average rating of “Hold” and a consensus target price of $55.20.

Qiagen Stock Down 1.3%

The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31. The business’s fifty day moving average price is $47.87 and its two-hundred day moving average price is $48.28. The stock has a market capitalization of $8.08 billion, a PE ratio of 19.41, a price-to-earnings-growth ratio of 1.98 and a beta of 0.70.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. During the same period in the previous year, the business posted $0.61 EPS. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, equities research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd raised its position in shares of Qiagen by 1,544.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 6,168 shares of the company’s stock worth $277,000 after acquiring an additional 5,793 shares during the period. MidFirst Bank acquired a new position in Qiagen in the 4th quarter worth about $154,000. Mercer Global Advisors Inc. ADV boosted its position in Qiagen by 12.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,475 shares of the company’s stock worth $336,000 after purchasing an additional 815 shares in the last quarter. OLD Mission Capital LLC purchased a new position in Qiagen during the fourth quarter worth approximately $494,000. Finally, Caisse de depot et placement du Quebec grew its holdings in Qiagen by 52.5% in the fourth quarter. Caisse de depot et placement du Quebec now owns 932,318 shares of the company’s stock valued at $42,539,000 after purchasing an additional 320,850 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.